Chronic Lower Back Pain Articles & Analysis
34 news found
(Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids. ...
“Approximately 50 million individuals in the United States suffer from chronic pain; unfortunately, many of these patients have limited treatment options that are safe or well tolerated and live with life-impacting pain that is not well managed. ...
("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive two-year follow-up data for the Company's StemSpine® pilot study, showing significant efficacy of the StemSpine® procedure for treating chronic ...
The StemSpine® publication demonstrates the clinical use of the patented procedure that utilizes a patient's own bone marrow aspirate for the treatment of chronic lower back pain. There were no safety related concerns at up to two years follow-up. The StemSpine® procedure resulted in an efficacy rate of 87% in the treated ...
Significant Drop in Mobility Due to Chronic Low Back Pain (CLBP) Demonstrated in New Mobility Index, with Highest Drop Among Those in Their 50s Treatment is Deficient with 15% Currently Taking Opioids Despite CDC Guidelines Noting Inadequate Effectiveness and Inherent Risks Only 5% Utilizing Recommended Minimally Invasive Treatment Options The Harris Poll, a Stagwell (NASDAQ: STGW) ...
Relievant Medsystems shared today that the company’s breakthrough chronic low back pain treatment, the Intracept Procedure, was featured on NBC’s TODAY this morning. The full segment can be viewed here. “This is an exciting story, not only for the patients I’ve treated, but also for the millions of patients with chronic vertebrogenic low back pain who will now learn about ...
Excite Medical recently displayed their groundbreaking spinal decompression machine at the Orlando Parker Seminar in Kissimmee, FL. Among dozens of products, the DRX9000 spinal decompression machine impressed healthcare and chiropractic professionals with its ability to alleviate chronic back and neck pain while simultaneously improving the wellbeing of patients. Excite was one of many vendors ...
Excite Medical, the leading provider of non-surgical spinal decompression machines for back pain and neck pain, recently showcased its innovative and groundbreaking DRX9000® spinal decompression machine at the Florida Chiropractic Association’s (FCA) Northeast Regional Convention and Expo, held at the World Golf Renaissance in St. Augustine, FL. Excite was one of dozens of vendors and ...
Excite Medical is proud to announce Lieutenant Colonel Todd Geohagan (ret.) as its first VP of Veteran and Military Affairs. LTC Geohagan served nearly 30 years in the United States Air Force. His experience and connection to the military community will be instrumental in expanding access to Excite’s innovative technology, while supporting those who have served, and are currently serving ...
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months. Salt Lake City, UT – February 25, 2022 – ...
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today that new Category I Current Procedural Terminology (CPT) codes for the Intracept Procedure are in effect as of January 1, 2022. The new Category I codes for the Intracept Procedure are: 64628: Thermal destruction of intraosseous basivertebral nerve, ...
DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company’s board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay’s total board membership to seven. “We are pleased to welcome these two transformational business leaders as new independent directors on the ...
There is a high unmet medical need in chronic pain, particularly among patients with concomitant opioid use problems. If approved, Buvidal could become an important therapeutic option for the management of chronic pain, adding to the current indication of treating opioid dependence”, says Dr. ...
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced 24-month results from a Level 1, prospective, randomized, multi-center trial (INTRACEPT) that further validate the safety, effectiveness, and durability of the Intracept® Procedure for patients with vertebrogenic CLBP. The study reported outcomes for ...
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced the Centers for Disease Control and Prevention (CDC) has designated an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code specifically for vertebrogenic low back pain. The new diagnosis code – M54.51 ...
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the appointment of Dave Amerson to the Company’s Board of Directors. “It is with great pleasure that I welcome Dave to our Board of Directors,” said Tyler Binney, President and Chief Executive Officer of Relievant. “Dave’s wealth ...
Dublin – Ireland, 29 June 2021 – Mainstay Medical Holdings plc (the “Company”) today announced the limited commercial launch in the U.S. of ReActiv8, its implantable Restorative Neurostimulation™ system to treat intractable chronic low back pain. The ReActiv8 system will be available in the U.S. through ReActiv8-certified physicians commencing in the summer of ...
Medtech start-up Gelmetix, the developer of a first-in-class polymer treatment for chronic lower back pain, has closed a successful £5 million Series C equity financing round. ...
The round is expected to fuel the company’s growth as it pursues FDA approval over the next year. the company’s EaseVRx solution recently became the first VR-based prescription therapeutic to receive breakthrough device designation from FDA for treatment-resistant fibromyalgia and chronic intractable lower back pain. ...
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the appointment of Tyler Binney as President and Chief Executive Officer. Mr. Binney will also join Relievant’s Board of Directors. Arthur Taylor, who previously held the CEO position on an interim basis, will return to his role on the Board of Directors. ...